Synonym
Ceftobiprole medocaril; Ceftobiprole medocaril sodium; BAL-5788; BAL 5788; BAL5788
IUPAC/Chemical Name
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(5-amino-1,2,4-thiadiazol-3-yl) (hydroxyimino)acetyl)amino)-3-((E)-((3'R)-1'-(((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)-2-oxo(1,3'-bipyrrolidin)-3-ylidene)methyl)-8-oxo-, monosodium salt, (6R,7R)-
InChi Key
MFAWUGGPPMTWPU-LCJFHXTKSA-M
InChi Code
InChI=1S/C26H26N8O11S2.Na/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18;/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31);/q;+1/p-1/b11-6+,30-15-;/t13-,16-,22-;/m1./s1
SMILES Code
O=C(C(N12)=C(/C=C3C(N([C@H]4CN(C(OCC5=C(C)OC(O5)=O)=O)CC4)CC/3)=O)CS[C@]2([H])[C@H](NC(/C(C6=NSC(N)=N6)=N\O)=O)C1=O)[O-].[Na+]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
712.64
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Falcó V, Burgos J, Almirante B. Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018 Sep;19(13):1503-1509. doi: 10.1080/14656566.2018.1516749. Epub 2018 Sep 10. PMID: 30198789.
2: Torres A, Mouton JW, Pea F. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations. Clin Pharmacokinet. 2016 Dec;55(12):1507-1520. doi: 10.1007/s40262-016-0418-z. PMID: 27272266; PMCID: PMC5107198.
3: Scheeren TW. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia. Future Microbiol. 2015;10(12):1913-28. doi: 10.2217/fmb.15.115. Epub 2015 Nov 17. PMID: 26573022.
4: Syed YY. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia. Drugs. 2014 Sep;74(13):1523-42. doi: 10.1007/s40265-014-0273-x. PMID: 25117196.
5: Azanza Perea JR, Sádaba Díaz de Rada B. Ceftobiprole: pharmacokinetics and PK/PD profile. Rev Esp Quimioter. 2019 Sep;32 Suppl 3(Suppl 3):11-16. PMID: 31364336; PMCID: PMC6755345.
6: Del Pozo JL, Patel R. Ceftobiprole medocaril: a new generation beta-lactam. Drugs Today (Barc). 2008 Nov;44(11):801-25. doi: 10.1358/dot.2008.44.11.1264007. PMID: 19180259.
7: Deitchman A, de Jong D, Barbour A, Derendorf H. Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections. Expert Rev Anti Infect Ther. 2016;14(11):997-1006. doi: 10.1080/14787210.2016.1244481. Epub 2016 Oct 2. PMID: 27690689.
8: Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788. Drugs R D. 2006;7(5):305-11. doi: 10.2165/00126839-200607050-00003. PMID: 16922591.
9: Awad SS, Rodriguez AH, Chuang YC, Marjanek Z, Pareigis AJ, Reis G, Scheeren TW, Sánchez AS, Zhou X, Saulay M, Engelhardt M. A phase 3 randomized double- blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014 Jul 1;59(1):51-61. doi: 10.1093/cid/ciu219. Epub 2014 Apr 9. PMID: 24723282; PMCID: PMC4305133.
10: Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health Syst Pharm. 2008 Aug 15;65(16):1545-51. doi: 10.2146/ajhp080032. PMID: 18693210.
